Tuesday, 15 December 2015

Geographical Indications: an Update

  • INTA – Geographical Indications Database
During the Geographical Names Conference organized by the International Trademark Association (INTA) held in Rome on December 10-11, 2015, INTA has launched a new online Member Resource on December 10, 2015.

The searchable online database will be a publication on Geographical Indications, Certification Marks and Collective Marks.

The Geographical Indications (GI) tag distinguish products on the basis of its geographical origins and prevents traders from claiming the attributes of a product which are specific to certain geographies to products produced in other areas. A GI tag grants exclusivity to a ‘community’ as a whole rather than individuals (legal entities), as in the case of trademarks and patents.

The said resource is available online on the website of INTA at http://www.inta.org/GeographicalIndications/Pages/GeographicalIndications.aspx and is accessible solely to INTA members. The resource is aimed at assisting attorneys in determining the procedure for protecting Geographical Indications, Collective marks and Certifications marks in select jurisdictions, whether under sui generis or other types of laws.
  • Basmati Rice – Indo-Pak Collateral Protection for GI Mark
As reported in Financial Express, an English Daily, basmati rice may finally be on its way to getting the much awaited and coveted GI tag and the protection associated with it.

Pakistan has reportedly agreed not to contest India’s move to include basmati, grown in parts of the Indo-Gangetic plain in its GI Registry, with the condition that when Pakistan puts in place a similar IPR (intellectual property rights) platform, it would also get the rice grown in its Punjab province registered under a GI system.

The long grained aromatic rice is produced in the foothills of the Himalayas (Punjab, Haryana, Jammu & Kashmir, Uttar Pradesh, Uttarakhand and Delhi, in India and the Punjab province of Pakistan).

The Intellectual Property Appellate Board, Chennai recently concluded hearing all stakeholders, in respect of the GI tag for basmati rice and is likely to issue a final notification in this regard, shortly. There have been various conflicting claims over the basmati, even within India.

GI recognition in India would result in protection of the tag in other countries including the European Union and the US. Since basmati was not covered under GI protection, many private companies from various jurisdictions have tried to register their products under the title, which is globally considered a high priced premium rice.

On this GI notification becoming a reality, farmers from 77 districts in 7 states in India would benefit. India currently has an 87% share in the global sales of basmati.

In 2013, the Centre had been asked by the GI Registry, whether the State of Madhya Pradesh (MP) could be included in the geographies which traditionally grow basmati. The same was strongly opposed by various stakeholders including, agriculture ministries. The MP government also moved the IPAB in this regard.

The Agricultural and Processed Foods Export Development Authority (APEDA), which operates under the Ministry of Commerce and Industry, subsequently told IPAB that MP’s claim was invalid. Under the Geographical Indications of Goods (Registration and Protection) Act, 1999, APEDA is designated to be the custodian of GI rights for farm produce.

APEDA had applied for exclusive (commercial) use of ‘basmati’ for a grain variety which is grown in the boundaries of the Indo-Gagentic plain, in 2009.

In the past, India and Pakistan also initiated steps to register basmati under GI as ‘joint heritage’ for protecting its premium market abroad, however, the bid was faced with opposition within Pakistan and was not fruitful. 
  • Tirur Paan (betel leaves) – GI Protection
As reported in Times of India, an English daily, farmers in and around Tirur, an important business centre in the State of Kerala, have been growing and exporting betel leaves (Tirur Paan), with a spicy aromatic flavor, to Pakistan via Middle East for over half a century.

The market for the said betel leaves is threatened by the exports of betel leaves from Sri Lanka being marketed as Tirur betel leaves in Pakistan. Popular in the Pakistani market as Tirur-Lanka Paan, the name has worked well in the favour of the farmers from Sri Lanka.

"It is our soil, climate, cultivation practices that give the leaves its unique flavour and spiciness which is not found anywhere else in the world. We can continue the vocation only if the product is exported to Pakistan. It is important that we protect our markets in Karachi and Lahore as it is just not viable to grow the crops for the local markets due to the high labour charges. Sadly, the Sri Lankan leaves are gaining upper hand in Pakistan at our cost. We hope that the GI tag would help us protect the heritage and legacy of Tirur Betel leaves in the Pakistan," Beeran Kutty, a farmer in the area, has stated.

The export for the Tirur Paan dropped drastically, also because of the geo-political differences between India and Pakistan, following the demolition of the Babri Masjid and the Kargil War. Sri Lanka filled the void in export of the said betel leaves.

In view of the above difficulties and in an effort to safeguard the rights (claim) of the Tirur farmers in their sole overseas market, the farmers with the help of the Intellectual Property Rights (IPR) Cell of Kerala Agricultural University, are making efforts to have the Tirur Paan leaves gain the GI tag.

Obtaining the GI tag would allow the farmers to enforce their rights overs the geographically attributed product worldwide.


SSR Women Uprising !!

S.S. Rana & Co. feels proud to announce that its Women’s football team has won the ADIDAS Uprising, Delhi Chapter for Women’s Football on December 13, 2015. In keeping with the firm’s Women Empowerment Policy, the Women’s Football match was aimed to promote health and sports among women.

The ADIDAS Uprising saw participation from 2 women’s teams from our firm.

Meanwhile, the Men’s football team of S.S. Rana & Co. was not far behind either, and gave a tough competition to the other teams to reach the quarterfinals of the Men’s Football Tournament.

The Adidas Uprising, Delhi was a congregation of sports lovers, and offered 14 sports – Basketball, Cricket, Football, Running, Badminton, Tennis, Cycling, Training, Yoga, Zumba, Rugby, Skateboarding, Table Tennis and Wall Climbing – over a period of 2 days on December 12-13, 2015. The football games of the ADIDAS Uprising, Delhi was organized at the Plaza Farms, Chhattarpur, New Delhi.


Tuesday, 8 December 2015

Justice T.S. Thakur Sworn in as 43rd Chief Justice of India


Justice T.S. Thakur being sworn-in as the 43rd Chief Justice of India by President Pranab Mukherjee at the Rashtrapati Bhawan, in New Delhi on December 03, 2015
Image source: The Hindu

Justice Tirath Singh Thakur was sworn in as the 43rd Chief Justice of India (CJI) on December 03, 2015 by the President of India, Sh. Pranab Mukherjee, at the Rashtrapati Bhavan in New Delhi, India.

Justice Thakur, at 63 years, is the senior-most judge of the Supreme Court of India, and he succeeded Justice H L Dattu who retired on December 02, 2015.

As a Supreme Court judge, he has headed the bench delivering significant verdicts pertaining to reforming the cricket controlling body BCCI in the wake of allegations of betting and spot-fixing scandal in the Indian Premier League, probe into the multi-crore chit fund scam known as Saradha scam, and the multi-million rupee NRHM scam, in which ex-UP minister Babu Singh Kushwaha is also an accused, besides other politicians and bureaucrats, to name a few.

Born on January 04, 1952, CJI Thakur will serve as the CJI for a little over one year and is slated to retire on January 04, 2017.

Earlier, CJI Thakur was appointed as a permanent judge in September 1995 and transferred to the Delhi High Court in July 2004. He was later appointed as acting Chief Justice of the Delhi High Court on April 9, 2008 and on August 11, 2008, he took over as Chief Justice of the Punjab and Haryana High Court. He was elevated as a judge of the Supreme Court and assumed charge on November 17, 2009.k
Delhi High Court stays transfer of pending IPR Cases to Lower Courts

In a recent judgment rendered in the case of Vifor (International) Ltd. v. The High Court of Delhi and Asian Patent Association (Indian Group) v. Registrar General, Delhi High Court, the Delhi High Court has stayed the transfer of pending Intellectual Property Rights cases to the lower courts irrespective of their pecuniary value.

Background

Pursuant to the Delhi High Court (Amendment) Act, 2015 (passed under the assent of the President of India on August 11, 2015), the pecuniary jurisdiction of the Delhi High Court was raised from INR 2 Million (USD 29,960*) to INR 20 Million (USD 299,601*). As a result, all suits valued below INR 20 Million (USD 299,601*) started being transferred to the lower courts for lack of pecuniary jurisdiction of the Delhi High Court. More details on the Delhi High Court (Amendment) Act, 2015 has been covered in our earlier newsletter and can be accessed here.


Thereafter, on October 23, 2015, the Commercial Courts, Commercial Division and Commercial Appellate Division of High Courts Ordinance, 2015 (hereinafter referred to as ‘Ordinance’) was promulgated and brought into force with immediate effect, under which commercial disputes (including Intellectual Property Rights matters) valued at INR 10 Million (USD 1,49,800*) were to be tried by Commercial Courts/ Commercial Division/ Commercial Appellate Division of the High Courts. More details on the said Ordinance has been covered in our earlier newsletter and can be accessed here.

Consequently, a petition was recently filed before the Hon’ble Delhi High Court seeking stay on the transfer of Intellectual Property Rights cases from the High Court to the lower courts inter alia, on the following grounds –

Contentions and Prayer of the Petitioners in the case

Prayer

In both the subject cases, the Petitioners had a common prayer that cases arising out of the Statutes, namely, the Patents Act, 1970, Trade Marks Act, 1999, Copyright Act, 1957, Designs Act, 2000 and The Geographical Indications of Goods (Registration and Procedure) Act, 1999 of value less than c are not required to be transferred in view of the proviso to Section 7 of the aforesaid Ordinance.

Contentions
  1. That as per the various provisions of the aforesaid five Acts, a suit would not lie in any Court inferior to a District Court.
  2. That the aforesaid proviso to Section 7 of the Ordinance would show that all suits and applications relating to commercial disputes stipulated by an Act lie in a Court inferior to a District Court, would pertain to the aforesaid Statutes.
  3. That in case any suit arising out of the aforesaid five IP Acts has already been filed on the Original Side of the High Court, the same is to be heard and disposed of by the Commercial Division of the High Court as per the proviso to Section 7 of the Ordinance. Thus, pending suits arising out of the said five Statutes are to be tried by the Commercial Division of the High Court even if their value is less than INR 10 Million (USD 1,49,800*).
  4. Additionally, in case an application for amendment of the plaint is filed, the respective Single Judges must hear and consider the same in accordance with law, as there are decisions that an amendment application can be entertained even if the jurisdictional value of the Court has changed (increased or decreased), and such a direction is required as amendment applications are not being accepted by the Delhi High Court’s Registry.
Contention on behalf of the Respondents

The Counsel for the Respondent contended that both the matters should be taken up in January, 2016 as the Ordinance is likely to be replaced by Act in the Winter Session of the Parliament which might also clear the ambiguities in the Ordinance.

The Court’s Observation and Order

The Delhi High Court (which is also a Respondent in the case), in view of the consideration that interpretation to proviso to Section 7 of the Ordinance requires deliberation, ordered that till the next date of hearing (i.e. January 19, 2016) cases arising out of the aforesaid five IP Acts shall not be transferred from the High Court to lower courts and in case application seeking amendment in pecuniary value is filed, they shall be considered by the respective Single Judges of the Delhi High Court in accordance with law.

Conclusion

The entire matter came up in light of Delhi High Court (Amendment) Act, 2015 which inter alia amended Section 5(2) of the Delhi High Court Act, 1966 pertaining to jurisdiction of the Delhi High Court as aforestated. However, Section 7 of the said Ordinance apparently creates an exception to the same with respect to commercial disputes. The clarity expected in the Ordinance would play a pivotal role in determining pecuniary jurisdiction (and subsequently court fee to be paid) of the Delhi High Court in cases of IP matters.

*@ 1 USD = 66.76 INR


Delhi High Court: Cipla has Infringed Roche’s Anti-Cancer Drug Patent

In a recent decision rendered in the cases F. Hoffmann-La Roche Ltd. & Anr. v. Cipla Ltd. (RFA (OS) 92/ 2012) and Cipla Ltd. v. F. Hoffmann-La Roche Ltd. & Anr. (RFA (OS) 103/ 2012), the Division Bench of the Hon’ble Delhi High Court has ruled that Cipla has infringed Roche’s patent in a lung cancer drug sold under the trade name Tarceva. Reportedly, Roche was selling its drug Tarceva at INR 4,800 per tablet whereas Cipla was marketing a generic version of the drug under the name Erlocip at the cost of INR 1,600 per tablet.

Brief facts

F. Hoffmann-La Roche Ltd. (hereinafter “Roche”) filed a suit to injunct Cipla Ltd. (hereinafter “Cipla”) from marketing a generic version of its lung cancer drug, Tarceva.

Roche’s plea for interim injunction against Cipla was dismissed by the learned Single Judge of the Delhi High Court on grounds of public interest involved and the life-saving nature of the drug in question.

Roche’s appeal to the Division Bench of this Court against the order passed the learned Single Judge was also dismissed in April, 2009, on the back of a heavily public interest-centric reading of the Patents Act, 1970, as amended from time to time, and a detailed discussion of the relative affordability of the two drugs to the common man. The decision is reported as F. Hoffman-La Roche v. Cipla Ltd. (2009) 40 PTC 125 (Del).

The Division Bench further felt that Cipla had done enough to demonstrate a potentially credible challenge to the validity of Roche’s patent No. IN ‘774, including raising sufficient doubt over whether IN ‘774 had complied with full disclosure requirements.

Thereafter, Roche approached the Supreme Court of India by way of a Special Leave Petition which was also denied, and the case moved to trial.

Meanwhile, Cipla had sought revocation of Roche’s patent in the impugned drug; however the same was refused by the Single Judge during trial.

Aggrieved by the decision of the Single Judge, both Cipla and Roche appealed against the Single Judge’s order before the Division Bench of the Delhi High Court.

Contentions raised by Roche
  1. Roche’s Patent IN 196774 was granted in February 2007 by the Indian Patent Office, which covered its patent rights over the Erlotinib Hydrochloride molecule which had demonstrated breakthrough capabilities as an Epidermal Growth Factor Receptor (EGFR) inhibitor which spiked survival benefit in cancer including non-small cell lung cancer (NSLC) patients.
  2. Roche alleged that Cipla had infringed its impugned drug under the name Tarceva by marketing the generic version of the drug under the name Erlocip.
  3. Cipla’s drug was also Erlotinib Hydrochloride and manufacture of Polymorph B by Cipla was sufficient to trigger infringement of Claim 1 of its patent IN ‘774.
Contentions raised by Cipla
  1. Roche’s patent IN ‘774 had not complied with full disclosure requirements as required under Section 8 of the Patents Act, 1970.
  2. Roche’s patent IN ‘774 is invalid             under Section 64 (1)(f) of the Patents Act, 1970 for lack of inventive step and for being obvious.
  3. Not only did Roche’s IN ‘774 specification fails to disclose how it was inventive but there were compelling evidences which indicated that it was more combination and less innovation.
  4. That the closest prior art to IN ‘774 and EP 0566226 (admitted as prior art) had extremely materially similar, if not identical, structures.
  5. That Roche had unsuccessfully applied for a Polymorph B form of Erlotinib Hydrochloride (Patent IN/507/Del), a claim which was rejected by the Indian Patent Office in 2008 with the findings on evergreening, structural similarities between IN ‘774 and EP ‘226 and a lack of conclusive comparative clinical data to prove efficacy.
  6. That invention is required to be product specific, where products have to have commercial manifestation, since infringement is relatable to “that product‟ which is patented and not to any “substance”.
  7. That while the patent sought to be enforced is for Polymorphs A+B, the product actually under manufacture by both Roche and Cipla is Polymorph B which ought to be assumed to be in the public domain and hence Cipla’s activities are non-infringing in nature.
Court’s Observations

The Division Bench of the Delhi High Court reversed the order of the Single Judge and passed a judgment in favour of Roche by holding that Cipla had infringed Roche’s impugned Patent for lung cancer drug. However, the injunction prayed for by Roche against Cipla in India was not granted considering that the life of the said patent would expire in March 2016. While arriving at its decision, the Division Bench made reference to a plethora of judgments dealing with the nuances of Patent Law including “inventive step”, “disclosures to be made under the Law” etc. and made the following observations:
  1. That it was not in dispute that Roche’s unsuccessful patent application in India (DEL ‘507) was for a Polymorph B form of Erlotinib Hydrochloride, a claim that had been rejected by the Indian Patent Office in 2008 with observations on evergreening and structural similarities between IN ‘774 and DEL ‘507.
  2. That the process claims for making Polymorph B in DEL ‘507 had already matured into Patent No. 231102 and only the product claims pertaining to Polymorph B were refused.
  3. That the purpose of Section 3(d) of the Patents Act, 1970 is to encourage incremental innovation in pharmaceuticals. It lays down a threshold for what subject matter would qualify as the “same” or “known” substance and what would qualify as a “new” substance. The purpose of this qualification is that when something is same/ known substance, then the derivatives of such a substance as enumerated in the Explanation to Section 3(d) would be covered under the same protection that exists for the known substance (which could also mean that if the known substance is not covered by a patent then the derivative would not be covered as well).
  4. That while the present patent covers Erlotinib Hydrochloride (or polymorphs A+B of the same), the rejection of the patent application for Polymorph B (DEL ‘507) by the Indian Patent Office leads to a direct conclusion that there was a lack of sufficient matter to suggest that Polymorph B qualified as a “new product” for consideration under Section 2(1)(j) of the Patents Act for patentability and should therefore be regarded for all practical purposes as the old product itself i.e. Polymorphs A+B.
In view of the aforesaid, the Division Bench of the Delhi High Court held that Cipla has infringed the said patent of Roche, and directed Cipla to render its accounts concerning the manufacture and sale of its generic drug Erlocip and also imposed a cost of INR 500,000/- on Cipla.

Conclusion

The Roche-Cipla dispute over the lung cancer drug “Erlotinib” was one of the initial patent disputes filed in the country and had been keenly watched ever since. The Division Bench of the Delhi High Court has referred to a plethora of judgments including that of foreign jurisdictions in order to arrive at the aforesaid decision. It is hoped that the final outcome of the infringement suit and the judgement would be helpful in deciding other similar pharmaceutical infringement disputes in India. 
Anchor’s “ALLROUND PROTECTION” not good enough to protect it from Colgate !

Division bench of the Hon’ble Delhi High Court on November 19, 2015 decided the appeal titled as ‘Colgate Palmolive Company & Anr. vs. Anchor Health and Beauty Care Pvt. Ltd.’ in favour of the Appellants/Defendants (herein after referred to as “Colgate”) and against the Respondent/Plaintiff (herein after referred to as “Anchor”).

The said appeal was filed against the order of the Single Judge allowing the application of the Plaintiff under Order VI Rule 17 of the Civil Procedure Code, 1908 (“CPC”), for amendment of the Suit Plaint.

Facts of the matter:

During the pendency of the suit filed by Anchor against Colgate for the use of “All-Around Decay Protection” on the carton launched in 2007, Anchor’s mark “Allround” (“impugned mark”) was registered on August 26, 2008. Thereafter, in December, 2011, Anchor filed the aforesaid application, to change the suit from a passing off matter to an infringement suit, which was allowed vide impugned order dated February 14, 2012.

Amendments sought by Plaintiff:
  1. Suit heading - “Suit for declaration and permanent injunction restraining infringement of registered trade mark/passing off, tortious acts of unlawful interference in the Plaintiff’s business, acts of unfair competition, economic duress and causing loss…” whereas original suit could not have been for “permanent injunction restraining infringement of registered trade mark” as the Anchor’s trade mark was not registered in 2007.
  2. Amendments would include averments that Anchor had sought registration of the impugned mark on September 2, 2005 and the same was granted during the pendency of the suit.
Order of the Single Judge:

The learned Single Judge was of the opinion that since the law of the amendment of pleadings is “rather liberal in nature” the amendments should ordinarily be allowed, “unless it is likely to prejudice the opposite party or is likely to take away a vested right which has accrued to the opposite party provided that opposite party can be compensated in terms of cost.”.

The learned Single Judge held that objection as to the suit being time-barred was without substance as suit was based on a continuing cause of action. The objection that the amendment permitted alteration of the suit from one kind to another was also overruled.

Contentions of the Appellants/Defendants:
  1. Original suit never disclosed that an application for registration of the impugned mark was pending in the name of Anchor. Further, the original suit claimed that the overall get up and description of the product by Colgate was similar to Anchor.
  2. Even if registration was granted in August, 2008, Anchor made no attempt to amend the suit at that point and only applied amendment of the suit in 2011, after the lapse of 3 year period.
  3. Relied on judgments of the Supreme Court, urging the general rule that parties are not allowed by amendment to set up a new case or cause of action which is barred.
Contentions of the Respondent/Plaintiff:
  1. Basic facts relating to confusion based on passing off were not undermined by the amendment, there was no fundamental change in the nature of the suit or the cause of action and in any case a fresh suit based on infringement could have been filed, that would not be time barred.
  2. The fundamental ground on which the suit is based continues to be the same if the amendment is allowed. It is not correct to say that anchor has added a new cause of action and what is introduced is only an additional ground, to challenge the use of the impugned mark by Colgate.
Observations and order of the Division bench:

In the original suit of Anchor, emphasis was on the use of the term “Allround Protection” which was used to describe its own toothpaste. The present suit is being filed to place on record the conduct of the defendants which are using all possible methods to curb healthy competition from the plaintiff.”

Anchor consciously did not seek to amend the suit, till December, 2011, for more than four years after filing of the suit and over 3 years and 2 months after securing registration of the impugned trade mark.

That Single Judge wrongly held that since the cause of action remained in respect of use of the term “Allround” which remained unchanged, no prejudice could be caused.
In view of the above, the present appeal of Colgate succeeded and the amendments allowed by the learned Single Judge were not to be made part of the record of the suit alongwith the subsequent amendments to the written statement. The impugned order was set-aside and application of Anchor dismissed.

Conclusion

It is once again clarified by the above judgement that Courts do not help protect the rights of those who have willingly/knowingly slept on their rights.

Anchor had no substantiated reason for not moving the court with an amendment application as soon as its trade mark was registered. In fact, the original plaint made no reference to its pending application in the impugned trade mark which in the eyes of the court goes to show that Anchor filed the suit in haste and waited too long to seek amendment thereof.

In general suits for injunction against passing off the Court may allow amendment plaint to make an infringement suits. However, in those cases the original plaint must contain the submission that an application for registration of trademarks is pending before the Trade Marks Registry.
Burberry's Square Device !





Burberry’s trade mark application No. 905510 for the device mark  has recently been advertised in the Trade Marks Journal No. 1719-0 dated November 16, 2015. The said application is in respect of articles of luggage, suitcases, bags, travelling bags, holdalls, handbags, wallets, purses, shoulder bags; toiletries and cosmetics bags, brief cases, satchels and portfolios, cases for personal organisers, parasols, umbrellas, walking sticks, key fobs and key holders; dog coats, all being goods falling under class 18 of the Nice Classification.



Burberry Group plc is a British luxury fashion house and an iconic British Luxury Brand established in 1856. It is known for its fashion products such as outerwear, fashion accessories, bags, fragrances, sunglasses, and cosmetics. Its distinctive tartan pattern/ Prorsum device , developed as far back as in the year 1901, has become one of its most widely copied trademarks. The company has branded stores and franchises around the world including India, and also sells through concessions in third-party stores. In 2014, Burberry was ranked 73rd in the Interbrand’s Best Global Brands’ report, ahead of Ralph Lauren and Hugo Boss. Burberry has more than 500 stores in over 50 countries including India.


Burberry’s popular checks have been in fashion since 1914, when Burberry was commissioned by the War Office to adapt its officer’s coat to suit the conditions of contemporary warfare, resulting in the “trench coat”. After the war, the trench coat became popular with civilians. The iconic Burberry check was created in the 1920s and used as a lining in its trench coats. Base products like the trench coat, the Piccadilly raincoat, the Cashmere scarf were all relaunched using notably the beige check known worldwide today.